Valuation dashboard for Opus Genetics, Inc. (IRD) with P/E N/A, P/B -40.38, EV/EBITDA -3.16 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation).
Analysis Summary
Trailing-twelve-month margins: gross margin 99.9%, operating margin -5.1%, net margin -10.9%.
At the current price of $5.41, IRD has negative trailing earnings (P/E not meaningful) and an ROE of 11.48%. Market capitalisation stands at $447M.
Balance sheet quality for IRD: current ratio of 6.4. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | -40.38 |
| EV / EBITDA | -3.16 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-0.26 |
| vs Current Price | -104.8% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| IRD | Opus Genetics, Inc. | $447M | 11.5% | ||
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $5.41 |
| Market Cap | $447M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | 1147.63% |
| Return on Invested Capital | -59.29% |
| Return on Assets | -115.75% |
| Gross Margin | 99.87% |
| Operating Margin | -513.47% |
| Net Margin | -1091.82% |
Related companies: ABOS · AGEN · ALEC · CGTX · HURA · INO · MCRB
Explore sector: Healthcare · Biotechnology
More sections of IRD: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks